Fourteen Republican‑led states have written to the Environmental Protection Agency urging it to add the abortion medication mifepristone to the Contaminant Candidate List (CCL). the letter , signed by attorneys general from Missouri, Alabama, Idaho and others, argues that at‑home abortions could be contaminating drinking water and potentially violating the Safe Drinking Water Act .

Fourteen GOP states ask EPA to list mifepristone

Missouri Attorney General Catherine Hanaway led the coalition that sent the request on behalf of 13 other states, including Texas, Florida and Kentucky. According to the attorneys general, the surge in self‑managed abortions following the 2023 removal of in‑person screening requirements has created a “waste stream” of pregnancy tissue and drug residues that enter municipal sewers. They contend that conventional treatment plants are not designed to filter out hormone‑disrupting chemicals, raising the specter of low‑level exposure for the general public.

EPA’s recent CCL expansion sets precedent

The push arrives just weeks after the EPA announced a broadening of the CCL to include hundreds of pharmaceuticals, such as antidepressants, in early April. In May, the agency confirmed that while mifepristone itself is not yet monitored, misoprostol – the second drug in the abortion regimen – has been added to the list.. As the report notes, inclusion on the CCL does not create a legal maximum contaminant level, but it signals to researchers that the compound warrants closer study.

Scientific debate over mifepristone’s wastewater persistence

Environmental health experts remain divided on whether mifepristone residues survive standard treatment processes. Some researchers point to preliminary studies indicating detectable hormone‑disrupting metabolites in treated water, while others argue that dilution and degradation render concentrations negligible. The Center for Environmental Health has called for “catch‑kits” with each prescription to capture waste, and a CEH spokesperson claimed that recent testing shows “high levels of progesterone‑disrupting chemicals” that can only come from at‑home abortions. According to the source, the agency’s scientists have yet to publish a definitive risk assessment.

Will EPA add mifepristone to the CCL?

The letter asks the EPA to place mifepristone on the CCL, a step that would trigger monitoring and possible future regulation. Critics warn that the move could be a strategic use of environmental law to curtail abortion access rather than a purely public‑health initiative. As the source indicates, the theory that medication‑abortion waste poses a widespread drinking‑water threat is still contested, and the EPA has not indicated a timeline for any decision.

Who will fund the needed research?

Even if the EPA agrees to monitor mifepristone, the cost of large‑scale sampling and analysis could fall to state health departments or private foundations. Some legislators have suggested that federal grant programs be earmarked for this purpose, while anti‑abortion groups argue that the pharmaceutical industry should bear responsibility. The outcome will likely shape both environmental policy and the legal landscape surrounding medication abortions in the United States.